Investors

Building toward the first disease-modifying treatment for osteoarthritis.

Building toward the first disease-modifying treatment for osteoarthritis.

Building toward the first disease-modifying treatment for osteoarthritis.

Cytonics is a clinical-stage biotechnology company developing CYT-108, an investigational engineered A2M therapy for knee osteoarthritis. Phase 1 is complete, and we are preparing a Phase 1b/2a trial designed to look for signs of disease modification.

Phase 1

Complete for CYT-108

10,000+

Patients treated with APIC™

25+

International patents

$40M+

Raised since inception

7,800+

Shareholders

63

Countries and territories

COMPANY OVERVIEW

A different way to build a biotech.

Since 2019, Cytonics has completed eight equity crowdfunding offerings on three platforms. In total the company has raised more than $40 million, including more than $25 million through equity crowdfunding, and today it is owned by 7,800+ shareholders in 63 countries and territories.

That independence keeps us focused on one goal: a treatment that changes the course of osteoarthritis.

Community-owned

Since 2019

From 500 to 7,800+ shareholders

Our shareholder base has grown more than 15× since our first crowdfunding offering in 2019, with owners in 63 countries and territories.

2019
2026

8 crowdfunding offerings

63 countries

Community-owned

Since 2019

From 500 to 7,800+ shareholders

Our shareholder base has grown more than 15× since our first crowdfunding offering in 2019, with owners in 63 countries and territories.

2019
2026

8 crowdfunding offerings

63 countries

Community-owned

Since 2019

From 500 to 7,800+ shareholders

Our shareholder base has grown more than 15× since our first crowdfunding offering in 2019, with owners in 63 countries and territories.

2019
2026

8 crowdfunding offerings

63 countries

PIPELINE

From the lab to the clinic

From the lab to the clinic

Our programs are built on one protein, A2M. Here’s where each one stands.

CYT-108 is an investigational therapy and has not been approved by the FDA. APIC™ is an FDA 510(k)-cleared device.

What comes next

01

Dose-optimization study

02

Type C meeting with the FDA to review the Phase 1b/2a trial design

03

IND filing

04

Phase 1b/2a trial

Investor presentation

Our investor presentation covers the science behind A2M, CYT-108’s clinical progress, our intellectual property and our plans for the next stage of development.

*Our updated investor presentation is coming soon. Leave your email and we’ll send it to you as soon as it’s ready.


Intellectual property

Cytonics holds 25 issued international patents and multiple pending applications covering recombinant A2M variants including CYT-108, methods of treating osteoarthritis and other inflammatory conditions, and processes for enriching A2M. Coverage spans the U.S., Europe, Canada, Australia, Japan and the U.K., with patent terms extending to at least 2040.

Strategic partners and prospective investors can contact us for a full patent list at: contact@cytonics.com

Disclosures

This website may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

Get updates on CYT-108 and the science behind it.

The company is “testing the waters” of a potential offering which will be conducted under a valid exemption under U.S. Securities laws. No money or other consideration is being solicited, and if sent in response, will not be accepted. Reservations and/or indications of interest involve no obligation or commitment of any kind on any party. This process allows companies to determine whether there may be interest in an eventual offering of its securities. The company is not under any obligation to make an offering. It may choose to make an offering to some, but not all, of the people who indicate an interest in investing. If the company does go ahead with an offering, it will only be able to make sales after it has filed offering documents with the Securities and Exchange Commission (SEC). The information in those offering documents will be more complete than the information the company is providing now, and could differ in important ways. You must read the documents filed with the SEC before investing.

This website may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

© 2026 Cytonics Corporation. All rights reserved.